Advertisement
DHR vs RGEN
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. Repligen Corporation (RGEN) Stock Comparison
Key Takeaways
- Danaher (DHR) is a diversified life sciences and diagnostics conglomerate with roughly $24.6 billion in 2025 revenue, steady free cash flow, and a dividend.
- Repligen (RGEN) is a pure-play bioprocessing technology company generating about $738 million in 2025 revenue with faster organic growth but greater volatility.
- Both companies reported solid fourth-quarter results, yet their risk profiles differ sharply: Danaher offers breadth and stability, while Repligen offers higher growth momentum tied to biotech funding cycles.
- Relative performance and market positioning diverge, making this comparison relevant for investors weighing a large-cap, diversified franchise against a mid-cap growth play.
- Analyst sentiment is broadly constructive on both names, though Repligen carries a wider range of price targets reflecting higher execution sensitivity.
Introduction
Danaher Corporation (DHR) and Repligen Corporation (RGEN) both operate in the life sciences ecosystem, but they represent very different ways to gain exposure to it. Danaher is a diversified industrial and medical technology giant spanning diagnostics, life sciences, and biotechnology, while Repligen is a focused supplier of bioprocessing consumables and instruments used to manufacture biologic drugs. This stock comparison is useful for traders and investors evaluating relative performance, growth drivers, and risk across two companies that respond differently to the same end-market forces. Understanding their contrasting market positioning can help clarify which profile better suits a given portfolio or trading strategy.
DHR Overview and Recent Performance
Danaher Corporation (DHR) is a Washington, D.C.-based science and technology conglomerate organized around three segments: Diagnostics, Life Sciences, and Biotechnology. Its portfolio includes brands such as Beckman Coulter, Cepheid, Leica Biosystems, SCIEX, and Cytiva. For the fourth quarter of 2025, Danaher reported revenue of $6.84 billion, up about 4.6% year over year, with adjusted earnings per share (EPS) of $2.23. Full-year 2025 revenue reached approximately $24.6 billion, up 3%, with adjusted EPS of $7.80, up 4.5%.
Recent market activity has been shaped by a recovery in bioprocessing, particularly in consumables, and solid diagnostics demand, offset by muted academic and government research spending. Management guided to 3% to 6% core revenue growth for 2026, supported by a constructive mergers and acquisitions (M&A) environment and a strong balance sheet. Danaher's diversified cash flows, 34 consecutive years of strong free cash flow conversion, and consistent dividend growth have reinforced its reputation as a relatively stable large-cap holding, even as insiders trimmed positions in recent months.
RGEN Overview and Recent Performance
Repligen Corporation (RGEN) is a Waltham, Massachusetts-based life sciences company that develops and commercializes bioprocessing technologies across four franchises: filtration, chromatography, proteins, and process analytics. Its products support upstream and downstream drug manufacturing, including perfusion systems and chromatography resins used in biologic and gene therapy production. For the fourth quarter of 2025, Repligen reported revenue of roughly $198 million, up 18% year over year (14% organically), with adjusted EPS of $0.49. Full-year revenue rose about 16% to $738 million.
Recent weeks have highlighted Repligen's above-market growth, led by strength in process analytics and proteins, alongside expanding gross margins and a record high-probability sales funnel. The company guided 2026 revenue to $810 million to $840 million and adjusted EPS of $1.93 to $2.01. However, Repligen's smaller scale, exposure to biotech funding cycles, and reliance on bioprocessing demand make its shares more volatile, and its stock has experienced periods of sharp drawdowns despite improving fundamentals. No dividend is paid, reflecting its growth-oriented capital allocation.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page offers a curated selection of AI trading bots. Tickeron operates hundreds of AI trading bots that trade thousands of different tickers, but only the best performers suited to current market conditions earn a place in this section, which typically highlights a focused group selected from a much larger pool of available robots. Each bot has its own trading style, strategy, timeframe, performance statistics, and set of tickers it trades, with metrics such as realized return, win rate, profit factor, and trade duration displayed transparently. Whether you favor short-interval momentum or multi-day swing strategies, exploring the Trending AI Robots list can help you identify approaches aligned with today's market environment.
Head-to-Head Comparison
The core contrast between DHR and RGEN is scale and diversification versus focus and growth. Danaher's business model spreads risk across diagnostics, life sciences instruments, and bioprocessing, generating low-single-digit organic growth with substantial recurring revenue and strong cash conversion. Repligen is a concentrated bioprocessing pure-play whose fortunes are more tightly linked to biologic drug manufacturing volumes and biotech capital availability, delivering mid-teens growth when demand recovers but amplifying downside during funding downturns.
On growth drivers, Danaher is leaning on a bioprocessing recovery, respiratory testing, and potential M&A, while Repligen is riding accelerating process analytics and proteins demand plus new product launches. Risk factors also differ: Danaher faces muted academic spending and China-related softness, whereas Repligen is exposed to customer concentration, gene therapy pacing, and higher valuation sensitivity. In terms of market sentiment, Danaher trades as a lower-beta, dividend-paying compounder, while Repligen attracts growth-oriented investors willing to accept more volatility for faster expansion.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor DHR in the current environment. Danaher's diversified revenue base, consistent earnings performance, robust free cash flow, and shareholder returns give it a more stable and predictable trend profile, which algorithmic systems typically reward. RGEN offers stronger growth momentum and an improving funnel, but its higher volatility and sensitivity to biotech funding introduce greater drawdown risk. That said, the verdict is probabilistic rather than definitive: momentum-focused AI models could lean toward Repligen during periods of sustained bioprocessing strength. The relative advantage depends on whether stability or growth is prioritized in the prevailing market regime.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DHR is a Hold and RGEN is a Hold.
Momentum Indicator for DHR turns positive, indicating new upward trend
DHR saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 57 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 63%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where DHR advanced for three days, in 179 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 111 of 195 cases where DHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for DHR turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 30 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
DHR broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.078) is normal, around the industry mean (67.298). P/E Ratio (40.824) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (1.361) is also within normal values, averaging (3.473). Dividend Yield (0.007) settles around the average of (0.002) among similar stocks. P/S Ratio (5.900) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. DHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
RGEN in downward trend: price dove below 50-day moving average on November 10, 2026
RGEN moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend. In 36 of 41 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 57 cases where RGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGEN as a result. In 71 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
The 10-day moving average for RGEN crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
Following a +6.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.636) is normal, around the industry mean (4.964). RGEN has a moderately high P/E Ratio (234.446) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DHR | RGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 29 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 77 | 88 | |
PRICE GROWTH RATING 1..100 | 18 | 40 | |
P/E GROWTH RATING 1..100 | 54 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (15) in the Medical Specialties industry is significantly better than the same rating for RGEN (99) in the Biotechnology industry. This means that DHR’s stock grew significantly faster than RGEN’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that DHR’s stock grew similarly to RGEN’s over the last 12 months.
DHR's SMR Rating (77) in the Medical Specialties industry is in the same range as RGEN (88) in the Biotechnology industry. This means that DHR’s stock grew similarly to RGEN’s over the last 12 months.
DHR's Price Growth Rating (18) in the Medical Specialties industry is in the same range as RGEN (40) in the Biotechnology industry. This means that DHR’s stock grew similarly to RGEN’s over the last 12 months.
DHR's P/E Growth Rating (54) in the Medical Specialties industry is somewhat better than the same rating for RGEN (97) in the Biotechnology industry. This means that DHR’s stock grew somewhat faster than RGEN’s over the last 12 months.
| DHR | RGEN | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 61% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 63% | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 64% | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 57% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 58% | 1 day ago 73% |
| Advances ODDS (%) | 3 days ago 56% | 4 days ago 73% |
| Declines ODDS (%) | 11 days ago 59% | 1 day ago 81% |
| BollingerBands ODDS (%) | 1 day ago 59% | 1 day ago 75% |
| Aroon ODDS (%) | 1 day ago 57% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 2 FA rating(s) are green while RGEN’s FA Score has 0 green FA rating(s).
- DHR’s FA Score: 2 green, 3 red.
- RGEN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 3 TA indicator(s) are bullish while RGEN’s TA Score has 2 bullish TA indicator(s).
- DHR’s TA Score: 3 bullish, 4 bearish.
- RGEN’s TA Score: 2 bullish, 6 bearish.
Price Growth
DHR (@Medical Specialties) experienced а +0.16% price change this week, while RGEN (@Pharmaceuticals: Other) price change was -3.13% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.83%. For the same industry, the average monthly price growth was -5.05%, and the average quarterly price growth was +38.36%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.09%. For the same industry, the average monthly price growth was +7.40%, and the average quarterly price growth was +22.84%.
Reported Earning Dates
DHR is expected to report earnings on Feb 03, 2027.
RGEN is expected to report earnings on Feb 24, 2027.
Industries' Descriptions
@Medical Specialties (-4.83% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+5.09% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -0.34% | ||
| TMO - DHR | 73% Closely correlated | -0.07% | ||
| RGEN - DHR | 68% Closely correlated | -0.78% | ||
| BIO - DHR | 64% Loosely correlated | -0.12% | ||
| A - DHR | 60% Loosely correlated | -0.52% | ||
| BRKR - DHR | 58% Loosely correlated | +0.27% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| STCE | 47.28 | 2.32 | +5.16% |
| Schwab Crypto Thematic ETF | |||
| DUST | 39.14 | 1.11 | +2.92% |
| Direxion Daily Gold Miners Index Bear 2X ETF (DUST) | |||
| SHRD | 24.22 | -0.01 | -0.02% |
| Arimathea Catholic Core Bond ETF (SHRD) | |||
| MBB | 91.11 | -0.12 | -0.13% |
| iShares MBS ETF (MBB) | |||
| SCO | 19.87 | -0.32 | -1.58% |
| ProShares UltraShort Bloomberg Crude Oil (SCO) | |||